Suppression of cortical spreading depression in migraine prophylaxis

被引:447
作者
Ayata, C
Jin, HW
Kudo, C
Dalkara, T
Moskowitz, MA
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Stroke & Neurovasc Regulat Lab, Charlestown, MA 02129 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Stroke Serv, Charlestown, MA 02129 USA
[3] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Neurosci Intens Care Unit, Charlestown, MA 02129 USA
[4] Hacettepe Univ, Fac Med, Dept Neurol, TR-06100 Ankara, Turkey
关键词
D O I
10.1002/ana.20778
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Topiramate, valproate, propranolol, amitriptyline, and methysergide have been widely prescribed for migraine prophylaxis, but their mechanism or site of action is uncertain. Cortical spreading depression (CSD) has been implicated in migraine and as a headache trigger and can be evoked in experimental animals by electrical or chemical stimulation. We hypothesized that migraine prophylactic agents suppress CSD as a common mechanism of action. Methods: Rats were treated either acutely or chronically over weeks and months, with one of the above migraine prophylactic drugs, vehicle, or D-propranolol, a clinically ineffective drug. The impact of treatment was determined on the frequency of evoked CSDs after topical potassium application or on the incremental cathodal stimulation threshold to evoke CSD. Results. Chronic daily administration of migraine prophylactic drugs dose-dependently suppressed CSD frequency by 40 to 80% and increased the cathodal stimulation threshold, whereas acute treatment was ineffective. Longer treatment durations produced stronger CSD suppression. Chronic D-propranolol treatment did not differ from saline control. Interpretation Our data suggest that CSD provides a common therapeutic target for widely prescribed migraine prophylactic drugs. Assessing CSD threshold may prove useful for developing new prophylactic drugs and improving upon existing ones.
引用
收藏
页码:652 / 661
页数:10
相关论文
共 79 条
[1]   Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis [J].
Alves, OL ;
Doyle, AJ ;
Clausen, T ;
Gilman, C ;
Bullock, R .
NEUROPROTECTIVE AGENTS, 2003, 993 :25-34
[2]  
Alves OL, 2003, ANN NY ACAD SCI, V993, P48
[3]   Antiepileptic effects of topiramate on amygdaloid kindling in rats [J].
Amano, K ;
Hamada, K ;
Yagi, K ;
Seino, M .
EPILEPSY RESEARCH, 1998, 31 (02) :123-128
[4]   Spreading depression: Imaging and blockade in the rat neocortical brain slice [J].
Anderson, TR ;
Andrew, RD .
JOURNAL OF NEUROPHYSIOLOGY, 2002, 88 (05) :2713-2725
[5]   Cortical inhibition is reduced in chronic and episodic migraine and demonstrates a spectrum of illness [J].
Aurora, SK ;
Barrodale, P ;
Chronicle, EP ;
Mulleners, WM .
HEADACHE, 2005, 45 (05) :546-552
[6]  
Ayata C, 2000, NEUROSCIENCE, V95, P639
[7]   Effects of repetitive transcranial magnetic stimulation on visual evoked potentials in migraine [J].
Bohotin, V ;
Fumal, A ;
Vandenheede, M ;
Gérard, P ;
Bohotin, C ;
de Noordhout, AM ;
Schoenen, J .
BRAIN, 2002, 125 :912-922
[8]   Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model [J].
Bolay, H ;
Reuter, U ;
Dunn, AK ;
Huang, ZH ;
Boas, DA ;
Moskowitz, MA .
NATURE MEDICINE, 2002, 8 (02) :136-142
[9]   Microarray analysis of rat brain gene expression after chronic administration of sodium valproate [J].
Bosetti, F ;
Bell, JM ;
Manickam, P .
BRAIN RESEARCH BULLETIN, 2005, 65 (04) :331-338
[10]   Cortical hyperexcitability in migraine patients before and after sodium valproate treatment [J].
Bowyer, SM ;
Mason, KM ;
Moran, JE ;
Tepley, N ;
Mitsias, PD .
JOURNAL OF CLINICAL NEUROPHYSIOLOGY, 2005, 22 (01) :65-67